Trinity Biotech (TRIB) Income from Continuing Operations (2009 - 2024)

Trinity Biotech has disclosed Income from Continuing Operations across 16 years of filings, most recently posting 15797000.0 for Q4 2024.

• Income from Continuing Operations for Q4 2024 came in at 15797000.0, down 187.11% year-over-year; the trailing twelve-month figure through Dec 2024 was 30793000.0 (up 16.49% YoY), and the FY2025 annual result was 37376000.0, down 19.73% from the prior year.
• Income from Continuing Operations came in at 15797000.0 for Q4 2024 at Trinity Biotech, down from 4794000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 10724000.0 in Q3 2020 to a low of 18335011.0 in Q2 2023.
• The 5-year median for Income from Continuing Operations is 5148000.0 (2023), against an average of 4155150.0.
• Across the five-year window, Income from Continuing Operations jumped 438.11% in 2020 and plunged 2026.0% in 2022, its largest moves.
• Trinity Biotech's Income from Continuing Operations stood at 9121000.0 in 2020, then sank by 138.52% to 3513000.0 in 2021, then tumbled by 186.25% to 10056000.0 in 2022, then jumped by 45.29% to 5502000.0 in 2023, then plunged by 187.11% to 15797000.0 in 2024.
• The last three Income from Continuing Operations figures came in at 15797000.0 (Q4 2024), 4794000.0 (Q3 2024), and 6951933.0 (Q2 2024), per Business Quant data.